Metastatic Colorectal Cancers Completed Phase 2 Trials for Irinotecan (DB00762)

Also known as: Colorectal Cancer Metastatic / Metastatic Colorectal Cancer / Metastatic Colorectal Cancer (MCRC) / Cancer - Metastatic Colorectal / Colorectal Cancer, Metastatic

DBCOND0063579 (Metastatic Colorectal Cancers)Completed2 IdentifierTitlePurposeDrugs
NCT02497157Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal CancerTreatment
NCT02063529FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal CancerTreatment
NCT02292758Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by SurgeryTreatment
NCT00508404Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal CancerTreatment
NCT02119026Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal CancerTreatment
NCT01862003Phase I/II Trial of Antagonism of HER in GI CancerTreatment
NCT02970916Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE PolymorphismsTreatment
NCT02181556Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal CancerTreatment
NCT00806663FOLFIRI and Sunitinib in Metastatic Colorectal CancerTreatment
NCT01220063RSHF in Colorectal CancerTreatment
NCT01321957Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal CancerTreatment
NCT00418938SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialTreatment
NCT00614393Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)Treatment
NCT02129257´╗┐Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal CancerTreatment
NCT00875771Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer PatientsTreatment
NCT00191984A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal CancerTreatment
NCT00254137Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.Treatment
NCT00286130Safety and Efficacy of Folfox6 + Cetuximab Versus Folfiri +Cetuximab in Patients With Metastatic Colorectal CancerTreatment
NCT00332163Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based TherapyTreatment
NCT00411450Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to TreatmentTreatment
NCT00475293Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRCTreatment
NCT00636610A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal CancerTreatment
NCT00689624Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal CancerTreatment
NCT00752570A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal CarcinomaTreatment
NCT00792363Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS MutationsTreatment
NCT00827684Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS MutationsTreatment
NCT00891930Study to Evaluate Mechanisms of Acquired Resistance to PanitumumabTreatment
NCT00959647A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer StudyTreatment
NCT00958386Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)Treatment
NCT01225744Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted TherapyTreatment
NCT01281761Simvastatin + Cetuximab/Irinotecan in K-ras Mutant Colorectal Cancer (CRC)Treatment
NCT01640444Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)Treatment
NCT01882868A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in JapanTreatment
NCT01163396First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal CancerTreatment
NCT03368859A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and BevacizumabTreatment